Allogene Therapeutics

ALLONasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$693.761 M

$2.01 +2.03%

Close of 7 Aug 2026

Revenue

$0.00

#3658 by revenue

Earnings

-$190.9M

Loss-making

Shares outstanding

243,777,920

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#57Candel TherapeuticsCADL$775.9M
#58Agomab TherapeuticsAGMB$714.1M
#59Allogene TherapeuticsALLO$693.8M
#60Tectonic TherapeuticTECX$584.6M
#61Zura BioZURA$566.7M

Where these numbers come from

Share counts and financials for Allogene Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.